- Home
- MOGU vs INAB Comparison
MOGU vs INAB Comparison
Compare MOGU & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOGU | INAB |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5M | 22.9M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MOGU | INAB |
|---|---|---|
| Price | $2.34 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $180.00 |
| AVG Volume (30 Days) | ★ 55.0K | 44.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.83 | $0.12 |
| 52 Week High | $8.10 | $4.20 |
Technical Indicators
Market Signals| Indicator | MOGU | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 31.06 |
| Support Level | $2.01 | $1.17 |
| Resistance Level | $2.95 | $2.55 |
| Average True Range (ATR) | 0.30 | 0.14 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 50.48 | 6.06 |
Price Performance
Historical ComparisonAbout MOGU MOGU Inc.
MOGU Inc is an online service provider in China, operating a KOL-driven online fashion and lifestyle platform, Mogujie, and providing customized online branding solutions to businesses. The company, on its platform, provides content related to fashion and lifestyle guides in various multimedia formats, which include Live Video Broadcasts, Short-form Videos, Photography, and an Online Review Community. The company derives revenues from within China. It also provides online marketing, commission, financing, technology, and other relevant services to merchants and users, as well as technology services to brand owners.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.